Page last updated: 2024-11-02

phenobarbital and Nephrotic Syndrome

phenobarbital has been researched along with Nephrotic Syndrome in 2 studies

Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.
phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.

Nephrotic Syndrome: A condition characterized by severe PROTEINURIA, greater than 3.5 g/day in an average adult. The substantial loss of protein in the urine results in complications such as HYPOPROTEINEMIA; generalized EDEMA; HYPERTENSION; and HYPERLIPIDEMIAS. Diseases associated with nephrotic syndrome generally cause chronic kidney dysfunction.

Research Excerpts

ExcerptRelevanceReference
" Based on the available data it seems that one may postulate the following conclusions: (1) that the distribution factors as well as changes in drug elimination capacities seem to play a role, perhaps with differing relative importance, during each of the maturational periods; (2) that the physicochemical properties of a drug and its dosage, as well as changes in the volume of distribution in children, in the course of certain disease states may have a significant effect on kinetics of drug disposition in the body; (3) that systemic clearance, a model independent parameter, rather than elimination half-life, a hybrid pharmacokinetic parameter, more accurately reflects elimination of some drugs from the body; (4) that each drug and every clinical situation may require the evaluation of the direct effect on pharmacokinetic processes, since general principles may not always apply; (5) that drug disposition studies should also be performed, if possible, on patients under actual clinical situations and receiving the usual therapeutic regime, and (6) that the half-life of colistin is independent of postnatal age which should serve as a warning not to generalize about drug excretion in the young infant."2.37Clinical pharmacokinetics of changes in drug elimination in children. ( Prandota, J, 1985)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19902 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Prandota, J1
Horiguchi, T1

Reviews

1 review available for phenobarbital and Nephrotic Syndrome

ArticleYear
Clinical pharmacokinetics of changes in drug elimination in children.
    Developmental pharmacology and therapeutics, 1985, Volume: 8, Issue:5

    Topics: Adult; Anti-Bacterial Agents; Brain Injuries; Child; Child, Preschool; Colistin; Cystic Fibrosis; Di

1985

Other Studies

1 other study available for phenobarbital and Nephrotic Syndrome

ArticleYear
[Clinical study on determination of blood thyroid hormone levels using the protein binding test--free thyroxine index in young children].
    Nihon Shonika Gakkai zasshi. Acta paediatrica Japonica, 1971, Volume: 75, Issue:9

    Topics: Age Factors; Androgens; Antithyroid Agents; Child; Child, Preschool; Down Syndrome; Dwarfism, Pituit

1971